[go: up one dir, main page]

BR0315781A - Composição para tratamento de infecção causada por vìrus flaviviridae - Google Patents

Composição para tratamento de infecção causada por vìrus flaviviridae

Info

Publication number
BR0315781A
BR0315781A BR0315781-4A BR0315781A BR0315781A BR 0315781 A BR0315781 A BR 0315781A BR 0315781 A BR0315781 A BR 0315781A BR 0315781 A BR0315781 A BR 0315781A
Authority
BR
Brazil
Prior art keywords
composition
infection caused
virus
flaviviridae
treating infection
Prior art date
Application number
BR0315781-4A
Other languages
English (en)
Inventor
Daniel Lamarre
Lisette Lagace
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR0315781A publication Critical patent/BR0315781A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO PARA TRATAMENTO DE INFECçãO CAUSADA POR VìRUS FLAVIVIRIDAE". A presente invenção refere-se a composições, uso, artigo de fabricação e método para tratamento de um mamífero infectado com um vírus da família Flaviviridae, compreendendo a administração ao mamífero infectado de um composto que apresenta a fórmula (I): em que A é selecionado dentre C~ 1~-C~ 6~ alquila e C~ 3~-C~ 6~ cicloalquila; B é selecionado dentre fenila ou tiazolila, ambos os quais sendo opcionalmente substituídos por um grupo selecionado de NH(R¬ 1¬) e NH(CO)R¬ 1¬, onde R¬ 1¬ é C~ 1~-C~ 6~ alquila; R é OH ou um derivado de sulfonamida, ou um sal farmaceuticamente aceitável do mesmo.
BR0315781-4A 2002-10-29 2003-10-24 Composição para tratamento de infecção causada por vìrus flaviviridae BR0315781A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42190002P 2002-10-29 2002-10-29
US44276903P 2003-01-27 2003-01-27
PCT/CA2003/001634 WO2004039833A1 (en) 2002-10-29 2003-10-24 Composition for the treatment of infection by flaviviridae viruses

Publications (1)

Publication Number Publication Date
BR0315781A true BR0315781A (pt) 2005-09-13

Family

ID=32233460

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315781-4A BR0315781A (pt) 2002-10-29 2003-10-24 Composição para tratamento de infecção causada por vìrus flaviviridae

Country Status (13)

Country Link
US (1) US20050159345A1 (pt)
EP (1) EP1558633A1 (pt)
JP (1) JP2006517196A (pt)
KR (1) KR20050061592A (pt)
AU (1) AU2003275852A1 (pt)
BR (1) BR0315781A (pt)
CA (1) CA2498642A1 (pt)
EA (1) EA200500610A1 (pt)
EC (1) ECSP055815A (pt)
MX (1) MXPA05004604A (pt)
NO (1) NO20052580L (pt)
PL (1) PL376409A1 (pt)
WO (1) WO2004039833A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DE602004031645D1 (de) * 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
US8765667B2 (en) 2008-08-20 2014-07-01 Michael Eissenstat HCV protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2385838A1 (en) 2009-01-07 2011-11-16 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2504344A4 (en) * 2009-11-24 2013-06-05 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
WO2011063501A1 (en) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP2618831B1 (en) 2010-09-21 2016-01-06 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9090653B2 (en) 2012-06-08 2015-07-28 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SG11201408047XA (en) * 2012-06-08 2015-01-29 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
KR101446049B1 (ko) * 2013-01-14 2014-10-01 전남대학교산학협력단 뎅기 바이러스 관련 질환의 치료 또는 예방용 조성물
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors

Also Published As

Publication number Publication date
US20050159345A1 (en) 2005-07-21
JP2006517196A (ja) 2006-07-20
NO20052580D0 (no) 2005-05-27
AU2003275852A1 (en) 2004-05-25
EA200500610A1 (ru) 2005-10-27
NO20052580L (no) 2005-07-20
EP1558633A1 (en) 2005-08-03
MXPA05004604A (es) 2005-07-13
KR20050061592A (ko) 2005-06-22
WO2004039833A1 (en) 2004-05-13
CA2498642A1 (en) 2004-05-13
PL376409A1 (en) 2005-12-27
ECSP055815A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
BR0315781A (pt) Composição para tratamento de infecção causada por vìrus flaviviridae
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
BR0210357A (pt) Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
BRPI0607817A2 (pt) processo para a preparação de compostos macrocìclicos
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BR0206266A (pt) Heterocìclicos de difenila substituìda útil para tratar infecção por hcv
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
NO20075723L (no) Tiazolforbindelser og fremgangsmater for anvendelse
BR0308495A (pt) Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
ATE512976T1 (de) Hemmer des hepatitis-c-virus
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
GB0612423D0 (en) Therapeutic agents
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
UY27333A1 (es) Nucleótidos 4` sustituidos
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BR0116299A (pt) Composto, composição farmacêutica, método para o tratamento ou profilaxia de uma infecção picornaviral em um mamìfero, e, uso de um composto
DE60217114D1 (de) Verbrückte bizyklische serinproteaseinhibitoren
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0207215B8 (pt) Derivados de pirazolopirimidinona tendo ação de inibição de pde7

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired